If you’re like many Dry Eye patients, you’re always on the lookout for new Dry Eye therapies, information about existing therapies, or wondering what might be on the horizon.
Here are our latest product updates. (View our advertising policy).
CyclASol®, Reduces Fluorescein Staining
According to its manufacturer, Novaliq GmbH, CyclASol, a preservative-free cyclosporine A solution, reduced corneal fluorescein staining in a phase 2 clinical trial for patients with moderate to severe Dry Eye.
Cyclosporine A is an antibiotic and the active ingredient in RESTASIS (a.k.a. IKERVIS). It’s good to hear about a preservative-free version, especially for those who might benefit from the drop, but would prefer to avoid long-term exposure to preservatives.
http://www.novaliq.com/2017/01/05/novaliq-announces-positive-topline-results-of-phase-2-clinical-trial-evaluating-cyclasol-in-adults-with-moderate-to-severe-dry-eye-disease/
Seciera™, Proprietary Cyclosporine A
Sun Pharma announced Phase 3 confirmatory clinical trial results for Seciera, another preservative-free cyclosporine A drop with a “patented, novel, proprietary nanomicellar formulation.”
http://www.sunpharma.com/media/press-releases
Klarity, Rehabilitates and Stabilizes
Imprimis announced exclusive rights to Klarity, a preservative-free, topical solution and gel containing chondroitin sulfate, for patients with Dry Eye. According to its press release, Klarity protects and rehabilitates the eye’s surface after surgery, wearing contact lenses, or in cases of moderate to severe Dry Eye. It treats edema and free radical formation associated with Dry Eye and “can serve as a cell membrane stabilizer.”
http://irdirect.net/prviewer/release/id/2426340
Cannabinoid-based Therapy (Yes, Cannabis)
Ora Inc. has been retained by AXIM Biotechnologies for product development and clinical trials on glaucoma and Dry Eye treatments using cannabinoid-based ingredients. From the sound of it, the therapy is likely focused on reducing pain or other discomfort, rather than treating any underlying cause of disease.
http://aximbiotech.com/wp-content/uploads/2017/05/AXIM_03212017_ORA-CSA-MEDIA_FINAL.pdf
Human Lubricin ECF843, Improves Dry Eye Signs
Novartis will in-license ECF843 (a human lubricin protein) worldwide (outside Europe). In a phase II study, with 28-days patients showed improved signs of Dry Eye. More testing is to be expected.
TrueTear™ Intranasal Tear Neurostimulator
The FDA recently approved Allergan’s TrueTear hand-held tear stimulator. The device has two prongs that emit small pulses. Choose the strength level, place prongs in nostrils, and voilà, tears!
Doctors sometimes place Q-tips in nostrils to test reflexive tear production, a tear that is more caustic then normal tear film. So, could TrueTear exacerbate Dry Eye symptoms?
Probing Restores Meibomian Glands
Although more studies are likely, and necessary, this one suggests meibomian glands can be restored, or regrown, with probing. That’s good news for anyone with obstructive meibomian gland dysfunction.
http://bjo.bmj.com/content/early/2017/06/06/bjophthalmol-2016-310097.full
P-321, Keeps Eyes Hydrated
Parion Sciences agreed to grant Shire “exclusive worldwide rights to develop and commercialize P-321. P-321 is “an investigational epithelial sodium channel (ENaC) inhibitor” for treating Dry Eye. P-321 may block tear absorption and keep the surface of the eye hydrated. Additional clinical studies are still required.
https://www.shire.com/en/newsroom/2017/may/o53zxn
Zerviate, for Allergies
Nicox received FDA approval for Zerviate, a topical eye drop containing the antihistamine cetirizine, for ocular itching associated with allergic conjunctivitis. Cetirizine is the active ingredient in Zyrtec. Allergic conjunctivitis can contribute to Dry Eye symptoms.
http://www.nicox.com/assets/files/ZERVIATE_FDA_Approval_20170531_EN.pdf
Send your questions and comments to blogger@notadryeye.org.
Subscribe to our blog to keep up with Not A Dry Eye.
Support Not A Dry Eye Foundation. When you shop at smile.amazon.com, Amazon donates 0.5% of your purchase.